U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIOTHYRONINE

SMILES

N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O

InChI

InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68014284

Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

1956
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

1956
Diagnostic
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

1956
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
346 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
404 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
342 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4740 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13938 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
4926 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
12929 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4370 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.04 h
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Disc. AE: Anxiety, Palpitations...
AEs leading to
discontinuation/dose reduction:
Anxiety (severe)
Palpitations
Agitation
Shortness of breath
Irritability
Tachycardia
Tremor
Sources:
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting
Abdominal pain
Headache (severe)
Confusion
Disorientation
Diplopia
Sources:
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 39 ± 6.2
Health Status: unhealthy
Age Group: 39 ± 6.2
Sex: M+F
Sources:
DLT: Anxiety, Tachycardia...
Dose limiting toxicities:
Anxiety (50%)
Tachycardia (50%)
Loose stools (100%)
Sources:
37.5 ug 2 times / day multiple, oral
MTD
Dose: 37.5 ug, 2 times / day
Route: oral
Route: multiple
Dose: 37.5 ug, 2 times / day
Sources:
unhealthy, 39 ± 6.2
Health Status: unhealthy
Age Group: 39 ± 6.2
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Irritability Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Palpitations Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Shortness of breath Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Tachycardia Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Tremor Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Anxiety severe
Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources:
unhealthy, 20
Health Status: unhealthy
Age Group: 20
Sex: M
Sources:
Abdominal pain Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Confusion Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Diplopia Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Disorientation Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Nausea Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Vomiting Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Headache severe
Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: F
Sources:
Loose stools 100%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 39 ± 6.2
Health Status: unhealthy
Age Group: 39 ± 6.2
Sex: M+F
Sources:
Anxiety 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 39 ± 6.2
Health Status: unhealthy
Age Group: 39 ± 6.2
Sex: M+F
Sources:
Tachycardia 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 39 ± 6.2
Health Status: unhealthy
Age Group: 39 ± 6.2
Sex: M+F
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle.
2006-03
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo.
2001-06-08
Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor.
2001-05-18
Circannual pattern of hypothalamic-pituitary-thyroid (HPT) function and mood during extended antarctic residence.
2001-05
Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus).
2001-04-15
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs.
2001-04
Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes.
2001-04
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions.
2001-04
Effect of thyroxine administration on the IGF/IGF binding protein system in neonatal and adult thyroidectomized rats.
2001-04
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary.
2001-04
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air.
2001-04
Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone.
2001-03-26
Effect of different drugs on the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto's thyroiditis and nontoxic nodal goiter.
2001-03-21
Regulation of microglial development: a novel role for thyroid hormone.
2001-03-15
Regulation of mucous differentiation and mucin gene expression in the tracheobronchial epithelium.
2001-03-07
Thyroid hormone receptors in neonatal, prepubertal, and adult rat testis.
2001-03-07
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase.
2001-03-06
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis.
2001-03
Effects of caloric restriction on skeletal muscle mitochondrial proton leak in aging rats.
2001-03
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus).
2001-03
The biological relevance of thyroid hormone receptors in immortalized human umbilical vein endothelial cells.
2001-03
Perioperative considerations in a hypothyroid infant with hepatic haemangioma.
2001-03
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism.
2001-03
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study.
2001-03
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion.
2001-03
Homogeneous enzyme immunoassay for triiodothyronine in serum.
2001-03
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression.
2001-03
Hormone selectivity in thyroid hormone receptors.
2001-03
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression.
2001-03
Role of thyroid hormones in hepatic effects of peroxisome proliferators.
2001-02-24
Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans?
2001-02-23
Relationships between plasma levels of organochlorines, retinol and thyroid hormones from polar bears (Ursus maritimus) at Svalbard.
2001-02-23
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism.
2001-02-15
Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease.
2001-02-15
What is the optimal treatment for hypothyroidism?
2001-02-05
Side-effects of iodized oil administration in patients with simple goiter.
2001-02
Changes in serum thyroid hormone levels in newborn calves as a diagnostic index of endemic goiter.
2001-02
[Diabetes mellitus caused by pancreatitis in a bull].
2001-02
Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study.
2001-02
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis.
2001-01
Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial.
2001-01
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
2001-01
Direct effect of thyroxine on pig sphincter of Oddi contractility.
2001-01
[Diagnosis of hyperthyroidism].
2001-01
Impairment in cognitive and exercise performance during prolonged antarctic residence: effect of thyroxine supplementation in the polar triiodothyronine syndrome.
2001-01
Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
2001-01
Effect of cold exposure on energy balance and liver respiratory capacity in post-weaning rats fed a high-fat diet.
2001-01
Endogenous depression, thyroid function and acupuncture.
2001-01
Neurofilament expression in cultured rat adenohypophysial cells.
2001
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome.
2001
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:01:23 GMT 2025
Edited
by admin
on Mon Mar 31 18:01:23 GMT 2025
Record UNII
06LU7C9H1V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYRONINE
Preferred Name English
LIOTHYRONINE
HSDB   INN   MI   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
LIOTHYRONINE [MI]
Common Name English
LEVOTHYROXINE SODIUM RELATED COMPOUND LIOTHYRONINE [USP IMPURITY]
Common Name English
T3
Common Name English
NSC-80203
Code English
LIOTHYRONINE [USP IMPURITY]
Common Name English
3,5,3'-TRIIODOTHYRONINE, L-
Common Name English
LEVOTHYROXINE SODIUM IMPURITY A [EP IMPURITY]
Common Name English
Liothyronine [WHO-DD]
Common Name English
LIOTHYRONINE [VANDF]
Common Name English
O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-L-TYROSINE
Systematic Name English
3,3',5-TRIIODO-L-THYRONINE
Systematic Name English
L-TYROSINE, O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-
Systematic Name English
3,5,3'-TRIIODOTHYRONINE
Systematic Name English
RATHYRONINE, (S)-
Common Name English
ALANINE, 3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)-, L-
Systematic Name English
T-3
Common Name English
TRIIODOTHYRONINE
Systematic Name English
THYRONINE, 3,3',5-TRIIODO-, L-
Systematic Name English
(2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID
Systematic Name English
liothyronine [INN]
Common Name English
LIOTHYRONINE [HSDB]
Common Name English
LIOTHYRONINE [USP-RS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.1715
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 83124-8
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 26879-7
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 83125-5
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
FDA ORPHAN DRUG 539116
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
NCI_THESAURUS C1553
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
WHO-VATC QH03AA03
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
NDF-RT N0000006165
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
CFR 21 CFR 862.1710
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
CFR 21 CFR 520.1284
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 3053-6
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 14930-2
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
WHO-ATC H03AA03
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 3055-1
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
NDF-RT N0000175946
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
NCI_THESAURUS C886
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LIVERTOX 1000
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 70152-4
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
NDF-RT N0000006165
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 35231-0
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
LOINC 57899-7
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
Code System Code Type Description
DAILYMED
06LU7C9H1V
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
RS_ITEM_NUM
1368008
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
CAS
57164-27-9
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
SUPERSEDED
DRUG CENTRAL
1585
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
EVMPD
SUB08527MIG
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023216
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
ECHA (EC/EINECS)
229-999-3
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
RXCUI
10814
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY RxNorm
SMS_ID
100000082541
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
NSC
80203
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
DRUG BANK
DB00279
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
MERCK INDEX
m6835
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY Merck Index
HSDB
3110
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
NCI_THESAURUS
C907
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
INN
653
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
FDA UNII
06LU7C9H1V
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
CHEBI
18258
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
LACTMED
Liothyronine
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
CAS
6893-02-3
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
WIKIPEDIA
LIOTHYRONINE
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL1544
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
IUPHAR
2634
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
MESH
D014284
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
CHEBI
533015
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
CAS
7013-53-8
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
SUPERSEDED
PUBCHEM
5920
Created by admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
The relative response factor is 1.00
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY